Mechanism of Action
Turmesac® is a synergistic phytochemical composition derived from the rhizome of Curcuma longa. Unlike turmeric ingredients based on a single isolated compound, it combines a spray-dried aqueous turmeric extract with curcuminoids and turmeric oil.
How Turmesac® works
The composition evaluated in the published research contained 95% spray-dried water extract of turmeric rhizome, 3% ethanolic curcuminoid extract and 2% turmeric oil. This broad phytochemical matrix provides water-extractable compounds, curcuminoids and volatile turmeric constituents that may act across several biological pathways.
Preclinical research indicates that Turmesac® works through a multi-target mechanism involving inflammatory cytokine modulation, control of oxidative stress, regulation of vascular permeability and protection of cellular architecture.
In activated immune cells, Turmesac® reduced the expression of the pro-inflammatory cytokines interleukin-8 and interleukin-12. In oxidative-stress models, it reduced intracellular reactive oxygen species and supported endogenous antioxidant systems. Animal studies also showed dose-dependent reductions in chemically induced edema, while cellular research identified apoptosis induction and cell-cycle modulation in selected cancer cell lines.
Together, these findings suggest that the mechanism of action is not dependent on one isolated molecular target. Instead, the phytochemical matrix appears to influence interconnected inflammatory, antioxidant and cellular-response pathways.
Modulation of pro-inflammatory cytokines
Inflammatory activation was studied in RAW 264.7 macrophages stimulated with lipopolysaccharide, or LPS. At the selected non-cytotoxic concentration of 50 µg/ml, Turmesac® substantially reduced the expression of IL-8 and IL-12.
The mean fluorescence intensity for IL-8 increased from 8.86 in untreated cells to 50.49 after LPS stimulation. Incubation with Turmesac® reduced this value to 19.63. IL-12 increased from 10.41 in untreated cells to 68.94 with LPS, but decreased to 15.79 following incubation with Turmesac®.
This cytokine-modulating activity provides a mechanistic basis for the reduction in inflammation observed in subsequent animal models.
Mean fluorescence intensity, LPS-stimulated RAW 264.7 macrophages, 50 µg/ml Turmesac®. Preclinical cellular data.
Regulation of vascular permeability and edema
Turmesac® was evaluated in croton oil-induced ear edema and histamine-induced paw edema models. In the croton oil model, the irritant activates protein kinase C and downstream inflammatory cascades involving cyclooxygenase-2, inducible nitric oxide synthase, eicosanoids, histamine release and increased vascular permeability.
Turmesac® produced dose-dependent edema inhibition. At 500 mg/kg, it inhibited croton oil-induced ear edema by 58.65% at two hours and 57.25% at four hours. It also significantly reduced histamine-induced paw swelling.
The study authors proposed that the histamine response may involve modulation of the H1 receptor or signalling molecules downstream of that receptor. They also reported reduced histamine-induced vascular endothelial growth factor production, suggesting a potential role in regulating vascular permeability and fluid movement into inflamed tissue.
These receptor and VEGF pathways are presented as proposed preclinical mechanisms rather than confirmed direct molecular targets.
Antioxidant defence and protection from cellular stress
Reactive oxygen species can damage cellular proteins, lipids, membranes and DNA when their production exceeds endogenous antioxidant capacity. In hydrogen peroxide-stressed HepG2 liver cells, intracellular ROS fluorescence increased to 52.5. Incubation with 50 µg/ml Turmesac® reduced the fluorescence value to 14.43, compared with 7.72 in untreated control cells.
This protective effect was also observed in a paracetamol-induced liver injury model. Turmesac® increased the antioxidant markers glutathione, superoxide dismutase and catalase while reducing elevated SGOT, SGPT and total bilirubin levels. At 500 mg/kg, liver tissue showed near-normal architecture with less necrosis, inflammation and fatty degeneration than the toxic control group.
These findings indicate that Turmesac® may support cellular defence by reducing oxidative burden, strengthening endogenous antioxidant enzyme activity and protecting the structural integrity of liver cells.
Apoptosis and cell-cycle control
In HeLa cervical adenocarcinoma cells, Turmesac® produced concentration-dependent inhibition of cell proliferation with an IC₅₀ of approximately 115.12 µg/ml. At this concentration, the total apoptotic cell population was reported as 83.93%, compared with 44.19% for the camptothecin reference compound. Changes were also observed in the sub-G0/G1 and S-phase cell populations, indicating interaction with apoptosis and cell-cycle regulation.
These results are limited to preclinical cellular research. They do not establish that Turmesac® prevents, treats or cures cancer in humans.
Mechanism flow
Turmeric rhizome
- Curcuma longa L.
Turmesac® phytochemical matrix
- Water-extractable turmeric compounds
- Curcuminoids
- Turmeric oil
Cellular and molecular targets
- IL-8 and IL-12 expression
- Histamine-associated signalling
- Vascular permeability and VEGF
- Intracellular ROS
- GSH, SOD and catalase systems
- Cell-cycle and apoptotic pathways
Biological responses
- Reduced inflammatory cytokine signalling
- Reduced edema and fluid extravasation
- Lower oxidative burden
- Improved endogenous antioxidant defence
- Protection of cellular and tissue architecture
- Apoptosis and cell-cycle modulation in selected preclinical cell models
Potential functional outcomes
- Healthy inflammatory balance
- Antioxidant protection
- Liver-cell protection
- Support for cellular resilience
Bioavailability and systemic retention
Bioavailability research on Turmesac® showed that both curcuminoid and polysaccharide fractions were detectable within 30 minutes, reached their highest reported plasma concentrations at approximately four hours and remained detectable at 24 hours. This profile is attributed to the complete phytochemical matrix and describes longer systemic retention than isolated curcumin and other turmerosaccharide preparations.
What this means for formulators
Turmesac® offers formulators a multi-component turmeric ingredient supported by in-vitro and in-vivo research across inflammatory, antioxidant, liver-protection and cellular-response models.
Its broad mechanism makes it relevant to formulations positioned for healthy inflammatory balance, antioxidant protection and liver-health support. It is well suited to instant beverages, wellness shots, gummies and capsules.
Finished-product dosage, claims and labelling should be determined through application-specific testing and regulatory review.
Request the mechanistic data package
Flow-cytometry data, edema-model results and liver histopathology are available in the Turmesac® scientific dossier.